Wells Fargo
STOK icon

Wells Fargo’s Stoke Therapeutics STOK Stock Holding History

Wells Fargo’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.66M Buy
50,835
+30,966
+156% +$994K ﹤0.01% 3750
2026
Q1 		$647K Sell
19,869
-29,716
-60% -$975K ﹤0.01% 4006
2025
Q4 		$1.57M Buy
49,585
+21,514
+77% +$647K ﹤0.01% 3629
2025
Q3 		$660K Buy
28,071
+5,066
+22% +$86.8K ﹤0.01% 4100
2025
Q2 		$261K Buy
23,005
+5,325
+30% +$50.6K ﹤0.01% 4610
2025
Q1 		$118K Buy
17,680
+894
+5% +$8.34K ﹤0.01% 5023
2024
Q4 		$185K Buy
16,786
+5,682
+51% +$69.8K ﹤0.01% 4840
2024
Q3 		$136K Sell
11,104
-283
-2% -$4.01K ﹤0.01% 4830
2024
Q2 		$154K Buy
11,387
+1,535
+16% +$20.7K ﹤0.01% 4681
2024
Q1 		$133K Buy
9,852
+1,352
+16% +$8.19K ﹤0.01% 4725
2023
Q4 		$44.7K Buy
8,500
+1,682
+25% +$7.19K ﹤0.01% 5317
2023
Q3 		$26.9K Sell
6,818
-3,689
-35% -$24.3K ﹤0.01% 5475
2023
Q2 		$112K Buy
10,507
+6,516
+163% +$69.3K ﹤0.01% 4972
2023
Q1 		$33.2K Buy
3,991
+3,891
+3,891% +$35.1K ﹤0.01% 5387
2022
Q4 		$923 Sell
100
-244
-71% -$2.54K ﹤0.01% 6209
2022
Q3 		$5K Sell
344
-231
-40% -$3.68K ﹤0.01% 5930
2022
Q2 		$8K Sell
575
-980
-63% -$14.9K ﹤0.01% 5852
2022
Q1 		$33K Sell
1,555
-6,486
-81% -$130K ﹤0.01% 5828
2021
Q4 		$193K Sell
8,041
-3,034
-27% -$72.4K ﹤0.01% 5287
2021
Q3 		$282K Buy
11,075
+6,046
+120% +$169K ﹤0.01% 4958
2021
Q2 		$169K Sell
5,029
-6,387
-56% -$226K ﹤0.01% 5096
2021
Q1 		$444K Buy
11,416
+3,386
+42% +$193K ﹤0.01% 4745
2020
Q4 		$497K Buy
8,030
+2,330
+41% +$107K ﹤0.01% 4524
2020
Q3 		$191K Sell
5,700
-4,571
-45% -$131K ﹤0.01% 4982
2020
Q2 		$245K Sell
10,271
-10,939
-52% -$260K ﹤0.01% 4795
2020
Q1 		$486K Buy
21,210
+3,180
+18% +$78.6K ﹤0.01% 4056
2019
Q4 		$510K Buy
18,030
+14,589
+424% +$367K ﹤0.01% 4347
2019
Q3 		$74K Buy
+3,441
New +$96K ﹤0.01% 5436

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo's STOK Position: Q2 2026 in Review

Wells Fargo increased its Stoke Therapeutics (STOK) stake by 156% in Q2 2026, buying an estimated $994K and bringing the position to 50,835 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #3750.

Wells Fargo first reported a position in STOK in Q3 2019 and has held it in 28 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Wells Fargo held 50,835 shares of Stoke Therapeutics worth $1.66M as of Q2 2026.
  • Wells Fargo bought 30,966 Stoke Therapeutics shares in Q2 2026, an estimated $994K.
  • Stoke Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #3750 holding.
  • Wells Fargo first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.